title: Cytogenetic analysis delineates a spectrum of chromosomal changes that can distinguish non-MALT marginal zone B-cell lymphomas among mature B-cell entities: a description of 103 cases.
abstract: The purpose of this study was to document the frequency and distribution of karyotypic changes present at diagnosis in 103 non-MALT marginal zone cell lymphoma (MZL) patients. This cytogenetic analysis of a large cohort extends previous observations and allows the identification of new cytogenetic features. Abnormalities identified in more than 15% of patients included +3/+3q (37%), 7q deletions (31%), +18/+18q (28%), 6q deletions (19%), +12/+12q (15%) and 8p deletions (15%). Trisomy 3/3q, 7q deletions, +18 and +12 were seen in different combinations in more than 30% of patients in comparison to 2% in lymphocytic lymphomas/chronic lymphocytic leukemias, 1% in mantle cell lymphomas and 7% in follicular lymphomas. The marked propensity of these abnormalities to be recurrently associated with the same tumoral clone of individual karyotypes allowed the delineation of a cytogenetic profile that may help to distinguish non-MALT MZL among other mature B-cell neoplasms. If +3/3q, +12/+12q, and 6q, 7q and 8p deletions were significantly associated with clinical prognostic factors previously reported to influence survival and time to progression, patients displaying these abnormalities did not experience a significantly shorter time to progression.
authors.affiliation: Service d'Hématologie Biologique, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France. evelyne.callet-bauchu@chu-lyon.fr
authors.forename: E
authors.initials: E
authors.lastname: Callet-Bauchu
authors.forename: L
authors.initials: L
authors.lastname: Baseggio
authors.forename: P
authors.initials: P
authors.lastname: Felman
authors.forename: A
authors.initials: A
authors.lastname: Traverse-Glehen
authors.forename: F
authors.initials: F
authors.lastname: Berger
authors.forename: D
authors.initials: D
authors.lastname: Morel
authors.forename: S
authors.initials: S
authors.lastname: Gazzo
authors.forename: C
authors.initials: C
authors.lastname: Poncet
authors.forename: C
authors.initials: C
authors.lastname: Thieblemont
authors.forename: B
authors.initials: B
authors.lastname: Coiffier
authors.forename: J P
authors.initials: JP
authors.lastname: Magaud
authors.forename: G
authors.initials: G
authors.lastname: Salles
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002869:Chromosome Aberrations; D015331:Cohort Studies; D020732:Cytogenetic Analysis; D018450:Disease Progression; D005260:Female; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis / Q000235:genetics; D016393:Lymphoma, B-Cell / Q000145:classification / Q000175:diagnosis* / Q000235:genetics*; D018442:Lymphoma, B-Cell, Marginal Zone / Q000145:classification / Q000175:diagnosis / Q000235:genetics*; D008224:Lymphoma, Follicular / Q000175:diagnosis / Q000235:genetics; D020522:Lymphoma, Mantle-Cell / Q000175:diagnosis / Q000235:genetics; D008297:Male; D008875:Middle Aged; D013997:Time Factors